The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process
- 5 April 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (13) , 1697-1702
- https://doi.org/10.1161/01.cir.0000161370.77463.0f
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Cardiovascular NewsCirculation, 2003
- Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient managementAmerican Heart Journal, 2002
- Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trialThe Lancet, 2001
- CAPRICORN: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-MIInternational Journal of Cardiology, 2001
- The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of CardiologyEuropean Heart Journal, 2000
- End-Point Interpretation in Clinical Trials: The Case for DisciplineControlled Clinical Trials, 1999
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureNew England Journal of Medicine, 1998
- Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart FailureNew England Journal of Medicine, 1993